AnaptysBio saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 69 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 in the early stages of their moves.
While AnaptysBio is not near an ideal buying range right now, see if it manages to form and break out from a proper consolidation.
AnaptysBio reported 0% earnings growth in its most recent report. Revenue increased 287%.
AnaptysBio earns the No. 101 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
